Benmelstobart

贝莫苏拜单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameBenmelstobart
Drug Alias NameTQB2450注射液安得卫CBT-502APL-502TQ-B2450 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaSolid tumoursEsophageal Diseases +[43] 
Global Approved IndicationsSmall Cell Lung Carcinoma
Approved Indications in ChinaSmall Cell Lung Carcinoma
Original Approved Country/TerritoryMainland China
Original Approved Date2024/04/30
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesApollomics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSino Biopharmaceutical LtdTianjin Medical University Cancer Institute And HospitalPeking University +[6] 
Inactive CompaniesShanghai Pulmonary HospitalFudan University
Active IndicationsSolid tumoursEsophageal DiseasesGastrointestinal Diseases +[29] 
Inactive IndicationsPrimary mediastinal B cell lymphomaDigestive System DiseasesUterine Cervical Neoplasms +[14] 

Other Information

ATC CodeN/A
Related LinksN/A